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Abstract
Background: Antibodies are the main effectors against malaria blood-stage parasites. Evaluation
of functional activities in immune sera from Phase 2a/b vaccine trials may provide invaluable
information in the search for immune correlates of protection. However, the presence of anti-
malarial-drugs, improper collection/storage conditions or concomitant immune responses against
other pathogens can contribute to non-specific anti-parasite activities when the sera/plasma are
tested in vitro. Purification of immunoglobulin is a standard approach for reducing such non-specific
background activities, but the purification method itself can alter the quality and yield of recovered
Ag-specific antibodies.
Methods: To address this concern, various immunoglobulin (Ig) purification methods (protein G
Sepharose, protein A/G Sepharose, polyethylene glycol and caprylic acid-ammonium sulphate
precipitation) were evaluated for their impact on the quality, quantity and functional activity of
purified rabbit and human Igs. The recovered Igs were analysed for yield and purity by SDS-PAGE,
for quality by Ag-specific ELISAs (determining changes in titer, avidity and isotype distribution) and
for functional activity by in vitro parasite growth inhibition assay (GIA).
Results: This comparison demonstrated that overall polyethylene glycol purification of human
serum/plasma samples and protein G Sepharose purification of rabbit sera are optimal for
recovering functional Ag-specific antibodies.
Conclusion: Consequently, critical consideration of the purification method is required to avoid
selecting non-representative populations of recovered Ig, which could influence interpretations of
vaccine efficacy, or affect the search for immune correlates of protection.
Background
Serological analysis of humoral responses is crucial for
vaccine evaluation as well as epidemiological studies for
identification of immune correlates. For both in vivo
(when passively transferred) and in vitro applications,
immunoglobulins need to be purified in order to not only
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eliminate potential pathogens but also to eliminate non-
specific effects of other serum components such as com-
plement, oxidative radicals, cytokines and drugs. Depend-
ing on the application, standard purification protocols are
either geared towards large scale purifications under
GMP-conditions of polyclonal Ab from immune individ-
uals [1-4] or towards the isolation of monoclonal Ab from
either biological fluids or culture supernatant for basic
research study or passive immunotherapy [5-8].
The majority of methods described in the literature are
based either on binding to certain subclasses of immu-
noglobulins (Igs) by molecules such as Protein A and G
[7] or on precipitating proteins in the size range of Igs
with reagents such as ammonium sulfate, (NH4)2SO4, [6],
caprylic acid/(NH4)2SO4 [9] or polyethylene glycol (PEG)
[10,11]. Some methods – here the exception being
(NH4)2SO4 and PEG protocols – require an acidic condi-
tion between pH 2–4 which can have a negative impact on
the quality, integrity and function of the purified antibody
molecules. In addition, the efficiencies of recovering a rep-
resentative pool of antibodies can vary by method.(e.g. for
human Igs Protein A binds preferentially to IgM and IgG
isotypes, but not to the IgG3 subclass). This is of particular
interest for disease models in which IgG3 acts as a marker
of exposure, such as in protozoan infections [12-14] as
well as for the mounting evidence that blood-stage spe-
cific IgG3 may be associated with protective immunity
against malaria depending on the target antigen [15-17].
In addition, IgG3 has been shown to be the most efficient
Ig isotype in mediating antibody-dependent cellular inhi-
bition (ADCI) at least in vitro [18]. Similar selectivity for
isotypes has been reported for murine as well as rat anti-
bodies. Igs from some species do not purify at all when
using Protein A or G [19].
Very limited information is available in the literature on
how the integrity and functional activity of antibodies are
affected by various purification methods; thus, a formal
comparison is needed to evaluate any differences. One
major focus point in malaria vaccine development is the
analysis of immune responses against the blood stage par-
asite of Plasmodium falciparum. Thus, model systems were
established based on sera from rabbits immunized with a
recombinant 42 kDa C-terminal portion of Merozoite
Surface Protein 1 (MSP-1p42) and plasma/serum from
malaria-exposed residents and respective malaria-naïve
rabbit- and human control sera. The methods chosen for
comparison were: (a) depletion of serum proteins by
caprylic acid followed by precipitation of Ig using
(NH4)2SO4, designated CA-AS; (b) enrichment of Ig using
PEG; (c) specific binding of IgG using Protein G Sepha-
rose; and (4) specific binding of IgM and IgG isotypes
using Sepharose coupled with Protein A/G. The recovery
from each method was determined by UV spectropho-
tometry and by Ag-specific ELISAs. The integrity of each Ig
preparation was tested by SDS-gel electrophoresis and the
ability of the isolated Ig to bind to their specific antigen
(Ag) was measured in MSP-1p42 specific ELISAs. Poten-
tial changes in the Ag-specific titer, isotype distribution
and Ab avidity were also determined by ELISA. Lastly,
conservation of biological function of purified Ig after
separation with the respective methods was tested by in
vitro parasite growth inhibition assays (GIA). This led to
the observation that the main difference between the
methods was in the yield of recovered Igs as reflected in
changes in the MSP-1p42-specific Ab titer. Overall, for
rabbit Igs, the purity was not significantly different, as
judged by SDS-gel electrophoresis, while for humans, it
was highest using Protein G, CA-AS and PEG. Biological
activity of the recovered Igs was retained for all prepara-
tions except for the PEG preparation of the rabbit Igs and
less for the Protein G and A/G preparations of the human
Igs. Thus, these observations led to the conclusion that
considerable qualitative and quantitative differences exist
between the Ig purification methods as a function of the
species of origin and thus suitable purification methods
must be chosen to avoid experimental artifacts which
could lead to mis-interpretation of vaccine effects or mis-
characterization of immune correlates.
Materials and methods
Source of MSP-1p42 specific Ab
New Zealand White rabbits (Spring Valley Laboratories,
Poolesville, MD) were subcutaneously immunized four
times with recombinant MSP-1p42 of the FVO strain (36
μg per immunization) [20] emulsified in complete (for
prime) or incomplete (for three booster immunizations)
Freund's adjuvant (Sigma Aldrich, St. Louis, MO). Rabbits
were exsanguinated four weeks after the last immuniza-
tion and the serum aliquots for this study were pooled.
Control sera were prepared by pooling sera from two rab-
bits immunized three times with 50 μg of reduced/
alkylated MSP-1p42 (FVO) in complete/incomplete Fre-
und's adjuvant. Human malaria-naïve sera were commer-
cially obtained from Interstate Blood Bank (Memphis,
TN). The malaria immune plasma samples were obtained
from adults living in a malaria endemic region of western
Kenya or from an individual having known immunity
against P. falciparum living in Gabon provided as a kind
gift from Prof. Alain Vernes (Bio Merieux, France) [21].
Immunoglobulin purification methods
(1) Enrichment of total immunoglobulin by a two step
sequential caprylic acid depletion of serum proteins fol-
lowed by ammonium sulfate precipitation of immu-
noglobulins was performed as essentially described earlier
[6,22].Malaria Journal 2008, 7:129 http://www.malariajournal.com/content/7/1/129
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(2) Selective enrichment of immunoglobulins using the
modified volume exclusion action of PEG from the SEP-
EASE (Polyclonal) Purification kit (Clinical Science Prod-
ucts, Mansfield, MA) was according to the manufacturer's
instructions.
(3) Specific binding of IgM and IgG to Ultralink™ Immo-
bilized Protein A/G Sepharose slurry (Pierce, Rockford,
IL). Protein A/G binds to all human IgG subclasses. For
this protocol, serum/plasma samples were diluted 1:10
using ImmunoPure® (G) IgG Binding Buffer (Pierce) and
batch-bound to 500 μl of pre-equilibrated 50% Ultral-
ink™ Immobilized Protein A/G Sepharose overnight at
4°C. The slurry was applied to a column by gravity flow
and allowed to pack. The flow-through was batch bound
a second time for 45 min at 22°C (RT) and again applied
to a chromatographic column. Bound Ig was eluted, at
500 μl per fraction, from the column using ImmunoPure®
(G) IgG Elution Buffer (Pierce) into tubes containing 20
μl of 1 M Tris-hydroxymethylaminomethane, pH 9.5 for
neutralization.
(4) Specific binding of IgG from serum/plasma samples to
1.0 ml pre-packed HiTrap™ Protein G columns (Amer-
sham Biosciences, NJ) was according to manufacturer's
instructions. Protein G binds to all human IgG subclasses,
but does not bind to human IgM. ImmunoPure® (G) IgG
Binding Buffer (Pierce) was used as the diluent, binding-
and wash buffer. Bound IgG was eluted in 1 ml fractions
using ImmunoPure® IgG Elution Buffer (Pierce) (tubes
were preloaded with 45 μl of 1 M Tris-hydroxymethylami-
nomethane, pH 9.5 for neutralization).
SDS gel electrophoresis
The various Ig fractions were first analysed by ELISA for
their MSP-1p42 specific titers, then adjusted to the titer of
their source sample (i.e., pre-purification sera/plasma)
followed by dilution as follows: all rabbit sera were
diluted 1:50 in 1× Tris-Glycine SDS sample buffer (Invit-
rogen, Carlsbad, CA) and human sera diluted into 1:10 in
1× Tris-Glycine SDS sample buffer for optimal band reso-
lution. Samples were loaded onto 4–20% gradient poly-
acrylamide Tris-Glycine gels (Invitrogen) and size-
fractionated by SDS gel electrophoresis (135 V, 90 min)
followed by Coomassie brilliant blue R-250 (Bio-Rad Lab-
oratories, Hercules, CA) staining. In some cases densitom-
etry was performed (Molecular Dynamics Inc.,
Densitometer Model 375, ImageQuant Fragment Analysis
version 1.1a) on the purified bands in order to determine
the degree of contamination with other protein bands.
Determination of protein concentration
The measurements for protein concentration were
obtained by absorption at 280 nm using the NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE) and an extinction coefficient of 13.5
(1% IgG solution). The NanoDrop spectrophotometer
was chosen for its 1) reduced path length (0.2 mm), mak-
ing it ideal for measuring small volume samples and 2)
high throughput capability.
ELISA
The titers of antigen-specific antibodies were measured by
ELISA in 96-well Immulon 2HB flat bottom microtiter
plates (Thermo, Milford, MA). The titers of rabbit sera
raised against MSP-1p42 (FVO) were determined using
the immunogen, i.e., recombinant MSP-1p42 (FVO). The
titers of human plasma obtained from semi-immune Ken-
yan blood were determined using recombinant MSP-1p42
(3D7). Plates were coated with 0.8 pmol/well of antigen
in a volume of 100 μl overnight at 4°C and blocked with
1× PBS with 1% BSA for 1 hr at RT. Serial two-fold dilu-
tions starting at 1:100 for human samples and 1:2,000 for
rabbit samples were prepared in 1× PBS/1% BSA and incu-
bated for 2 hrs at 22°C. Bound antibodies were detected
for 1 hr at 22°C using alkaline phosphatase-conjugated
goat-anti-rabbit (Fc-specific) diluted 1:4,000 or mouse-
anti-human (heavy and light chain specific) IgG
(Promega, Madison, WI) diluted 1:1,000. Microtiter
plates were developed at 22°C for 1 hr using 1 mg/ml of
4-nitrophenyl phosphate disodium salt hexahydrate tab-
lets (PNPP) (Sigma-Aldrich, St. Louis, MO) dissolved in
Alkaline Phosphatase Buffer (100 mM Tris-HCl, 100 mM
NaCl, 5 mM MgCl2) pH 9.5. Titer was defined as the dilu-
tion of serum or plasma that yielded an optical density of
1.0 at 405 nm (OD405 1.0). In order to correlate data
between each assay, a pool of serum from five high-titer
Kenyan adults and high-titer sera from MSP-1p42 (FVO)
immunized rabbits served as standard plate reference
samples.
Avidity
The avidity of antigen-specific antibodies in serum and
purified Ig was measured by indirect competitive ELISA
using sodium thiocyanate (NaSCN) as previously
described [23,24]. Rabbit sera and human plasma were
diluted in 1× PBS/1% BSA according to the OD405 1.0 titer
value previously determined. The diluted serum was
added directly to MSP-1p42-coated wells and incubated
for 2 hrs at 22°C. Antigen-antibody interactions were dis-
rupted by the addition of increasing concentrations of the
chaotropic agent NaSCN in PBS (ranging from 0.09 to 6
M NaSCN or 1× PBS (reference point) for 30 min at 22°C.
Plates were then washed to remove the NaSCN and proc-
essed following the standard ELISA protocol. The effective
concentration of NaSCN required to release 50% of spe-
cific serum antibodies (ED50) was determined and used
to compare the avidity of the antibodies recovered by the
various purification methods.Malaria Journal 2008, 7:129 http://www.malariajournal.com/content/7/1/129
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IgG isotype subclass
The immunoglobulin G isotype distribution in human
sera [21] and purified Ig was measured by indirect ELISA.
Plates were coated overnight at 4°C with 3.2 pmol/well of
MSP-1p42 3D7 (final volume, 100 μl/well). Plates were
blocked with 300 μl per well of 1× PBS/1% BSA for 1 hr at
37°C. Human sera were diluted 1:40 in 1× PBS/1% BSA
and added in serial two-fold dilutions to assay plate.
Bound antibodies were detected after 2 hr at 22°C using
1,000-fold diluted alkaline phosphatase-conjugated anti-
human (H&L) IgG (Promega) in positive control wells
and peroxidase-labeled anti-human IgG1, IgG2, IgG3,
and IgG4 (The Binding Site, Birmingham, UK) at dilu-
tions of 1:3,200 for IgG1, IgG2, IgG3 and 1:6,400 for
IgG4. Plates were developed by adding 100 μl of a 1:1
ratio of ABTS Peroxidase Substrate Solution A and Peroxi-
dase Substrate Solution B (Kirkegaard and Perry Laborato-
ries, Gaithersburg, MD) and incubating for 1 hr at 22°C.
Optical density was measured at 405 nm. Positive isotype
responses were reported as any value exceeding the calcu-
lated mean OD405 value plus two times its standard devi-
ation. For normal human serum the background values
for IgG1, IgG2, IgG3, and IgG4 were calculated as 0.36,
0.25, 0.21, and 0.11, respectively.
Parasite cultures and growth inhibition assays
Plasmodium falciparum FVO parasites were maintained
asynchronously in media consisting of RPMI 1640 (Invit-
rogen) with 25 mM HEPES, 7.5% w/v NaHCO3 and 10%
human pooled serum (blood type A+). Parasites were syn-
chronized using a 40/70% Percoll gradient two days prior
to assay setup. Cultures to determine growth inhibition
were set up at the schizont stage and continued for one
cycle (44 hrs) in 384 well plates. Parasite growth inhibi-
tory activities were measured by quantifying parasite lac-
tate dehydrogenase (pLDH) activities as described
previously [25].
Results
Antibodies exhibit species-specific as well as isotype-spe-
cific differences in regards to molecular weight, charge
and extent of glycosylation. These differences are expected
to affect the quality and efficiency of their recovery when
using different purification methods. Non-specific Ig puri-
fication methods rely on the chemical properties of Igs to
"precipitate" proteins based on their molecular charge or
weight (i.e. (NH4)2SO4, SEP-EASE), while the "specific"
methods rely on the ability of proteins (i.e. Protein A, G)
to bind the Fc portion of the immunoglobulins.
Thus, two precipitation methods and two affinity chroma-
tography-based separation methods were compared for
purifying rabbit and human Igs as summarized in the
Purification Scheme (Figure 1). Samples used for this
comparison were: (1) pooled sera from rabbits immu-
nized with a negative control Ag (reduced and alkylated
MSP-1p42 (FVO)); (2) pooled sera from rabbits immu-
nized with MSP-1p42 (FVO); (3) sera from normal blood
banked US individuals; and (4) plasma or serum from
malaria-experienced donors having high Ab titer against
P. falciparum MSP-1 induced by natural exposure. First,
the purified Igs were quantified for total protein concen-
tration (by 280 nm absorption) and for MSP-1p42-spe-
cific antibody-titer (by ELISA). Second, the Ig fractions
were analysed for purity and integrity by SDS-gel electro-
phoresis and for changes in the isotype distribution and
the avidity of antibody binding by ELISA. Lastly, the Ig
fractions were tested for changes in their biological activ-
ity against parasites compared to their respective pre-treat-
ment sample.
Purity of Ig isolated by the different methods
Analysis of purified Ig by SDS gel electrophoresis allows
the determination of (a) the degree of contamination with
other serum proteins and (b) the extent of degradation/
proteolytic processing in the recovered Ig fractions (Figure
2). To this end, individual batches of Ig purified by the
various purification methods were size-fractionated using
SDS-gel electrophoresis followed by analysis of Coomas-
sie Blue staining for the presence of contaminating bands
as well as evaluation for purity based on the density of the
purified Ig bands. With regard to purity, scanning densit-
ometry revealed that the majority of the protein obtained
corresponded to intact Ig, with purity at greater than 95%
for all rabbit (Panel A) and human Ig samples (Panel B).
Western blots probed with either anti-rabbit Ig alkaline
phosphatase conjugate or anti-human Ig-AP conjugate
confirmed that all visible lower molecular weight bands
reacted with the detecting antibodies thus indicating
some proteolysis or degradation of the Ig. For rabbit Igs,
all methods yielded high levels of intact pure Igs. For
human Igs, Protein G, PEG and CA-AS yielded highly
purified intact Ig while the Protein A/G method recovered
slightly more proteolysed Igs (Panel B, Lane 5). Based on
total yields, the lowest recovery was from the PEG method
for the rabbit Ig and from the CA-AS method for the
human Ig. Next, the stability of the various Ig preparations
was determined since Ig purification is often used to ship
and store samples in an attempt to eliminate reported
serum/plasma toxicity. For this purpose, human Ig prepa-
rations were stored for 24 weeks at 4°C and the SDS gel
electrophoresis was repeated (Panel C). While PEG and
CA-AS preparation did not show significant degradation,
extensive proteolysis was observed in the Protein G and
Protein A/G preparations. Table 1 summarizes the total
protein concentrations (measured by absorbance at 280
nm); mean ELISA titers, recovery of MSP-1p42 specific
IgG (adjusted for volume changes) and the purity of the Ig
preparations (determined by densitometry).Malaria Journal 2008, 7:129 http://www.malariajournal.com/content/7/1/129
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Efficiency of purification methods differs depending on the 
species of Ig donors
Although the Ig recovery and purity in most cases was
high, as shown in Figure 2, the decision was made to char-
acterize the recovered Igs by Ag-specific ELISA assays since
protein assays do not distinguish between Igs and any
other bands present. This would not only yield informa-
tion on changes in MSP-1p42 specific IgG titer, but also
measure the quality of the recovered Ig, i.e., whether the
Igs can still bind to their specific antigen and whether the
secondary detecting Ab in the ELISA still recognizes the
IgG (Figure 3). Comparison of Ag-specific IgG titers in the
various Ig preparations as a function of the purification
method did not distinguish significant differences when
using rabbit sera as source material, albeit PEG and Pro-
tein A/G consistently trended toward lower MSP-1p42-
specific titers. However, for human IgG preparations puri-
fied by the different methods, significantly lower titers in
Igs purified with either CA-AS or Protein A/G Sepharose
were observed (p = 0.025, One way ANOVA followed by
Tukey post-test). PEG reliably yielded the highest recovery
of MSP-1p42 specific human Ab.
Impact of purification methods on the isotype subclass 
distribution in Ig preparations
Immunoglobulins have distinct biological functions
which are governed by the heavy chain of the Ab mole-
cule. The heavy chain differs between Ig isotypes and
mediates binding to isotype-specific Fc receptors and/or
binding and activation of complement. Thus, a method
used for purifying functional antibodies should not bias
the purified Ab isotype profile. To this end, the four
selected purification methods were evaluated for causing
a change in the isotype profile (Figure 4). Ig preparations
obtained after purifying malaria-immune sera were ana-
lysed in a MSP-1p42 specific ELISA followed by an isotype
subclass specific detection step using secondary antibod-
ies against IgG1, IgG2, IgG3 or IgG4. While Protein G and
PEG did not show any relative bias in the separation of
MSP-1p42 specific IgG antibodies, not all methods were
equivalent relative to their ability to recover all isotype
subclasses. Only with the PEG method no significant
change for IgG1, IgG2, and IgG4 was detected, while for
IgG3, a significantly higher proportion of MSP-1p42 spe-
cific Ab was detected compared to the pre-treated source
material (Figure 4).
Procedure overview Figure 1
Procedure overview. Igs from either rabbit or human serum/plasma were purified (Step 1) and then biochemically charac-
terized in (Step 2), and finally evaluated for the retention of biological activity (Step 3). Each method was tested in at least three 
independent experiments.
Rabbit sera 
 Pre-immune
 Vaccine induced
Human serum/plasma (natural exposure)
 Normal blood bank
 Immune, natural exposure
Step 1 Precipitation Methods
 SEP-EASE (PEG method)
 Caprylic acid/(NH4)2SO4
Affinity Chromatography Methods
 Protein G sepharose
 Protein A/G sepharose
Step 2 Biochemical Characterization of Igs
Quantification
 Concentration of total Ig (NanoDrop)
 Concentration of Ag-specific IgG (ELISA titer)
Purity and Integrity
 SDS-PAGE
 Isotype specific MSP-1p42 ELISA
 Affinity ELISA
Step 3 Biological Characterization of Igs (Growth Inhibition Assay)
Source MaterialMalaria Journal 2008, 7:129 http://www.malariajournal.com/content/7/1/129
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Purification methods do not affect the avidity of MSP-
1p42 specific Ab
CA-AS as well as affinity chromatography using Protein A/
G or G alone involved adjustment of the sample to a low
pH at some point during the purification process, which
may result in the degradation of the Ig or affect Ag-recog-
nition. Therefore, the purified human and rabbit Igs were
tested for their binding strength to their specific Ag (MSP-
1p42) using an "avidity ELISA" which employed the cha-
otropic agent NaSCN. Samples from three independent
purification experiments were tested and no changes in
the binding avidity (ED50 = 2.0 M for both, rabbit and
human sample) were observed, regardless of the purifica-
tion method.
Purification methods can affect the biological activity of 
MSP-1p42 specific Ig
Finally, it was determined whether any of the selected
purification methods altered the biological function of
the isolated Ig (Figure 5). The concentration of MSP-1p42
specific Ig from each process was adjusted to the same titer
as its pre-treatment serum/plasma sample and then tested
for retention of its in vitro parasite growth inhibitory activ-
ity using a pLDH based GIA assay [25]. Differences in the
concentration of Ag-specific Ig due to the efficiency of the
purification method were excluded by normalizing the
samples based on their ELISA Ab titers. As a result, only
changes in the biological activity as a function of the
method would be revealed. When comparing the activi-
ties in rabbit Ig preparations, the only method that nega-
tively impacted GIA activity was PEG (p = 0.006 Kruskal
Wallis with Dunn's post test for the differences between
the methods and only PEG yielded lower biological activ-
ity compared to the source material p < 0.001). For
human Ig preparations (Figure 5, Panel B), Protein G and
Protein A/G were inferior to the other methods tested (dif-
ferences between the methods p < 0.001 ANOVA with
Tukey's post-test, Protein G and Protein A/G identified as
different from source material by paired T-test, p < 0.001).
Ig purity depends on the species of the source material Figure 2
Ig purity depends on the species of the source material. MSP-1p42 specific titers of the Ig preparations, Panel A (rabbit 
samples), Panel B, C (human samples) were determined by ELISA and then adjusted to the pre-purification titer. All rabbit sam-
ples were diluted 1:50 and all human samples were diluted 1:10 to achieve optimal band resolution. Lanes: 1) molecular weight 
marker, 2) source material (pre-purification), 3) MW marker, 4) Protein G-purified Ig, 5) Protein A/G-purified Ig, 6) CA-AS-
purified Ig and 7) PEG-purified Igs. Samples in Panel A, B were tested immediately following purification. Samples in Panel C 
were tested for their stability after storage for 24 weeks at 4°C. Panel C, 1) MW marker, 2) Protein G-purified Ig, 3) Protein 
A/G-purified Ig, 4) CA-AS-purified Ig and 5) PEG-purified Igs.
A
Rabbit
250
98
64
50
36
30
16
B
Human
250
98
64
50
36
30
16
250
98
64
50
36
30
16
C
Human-Stability
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Table 1: Choice of Purification Method for high yields is dependent on the species.
Sample Purification
method
Average Conc.
(mg/mL)1
Mean ELISA Titer2 Recovery of Ag-
specific Igs (%)3
Purity of Ig
preparation (%)4
Stability at 
4°C5
Pre-purification 1.3 × 106 (1.9 × 105)
Immune Rabbit CA-AS 12.3 1.4 × 106 (3.6 × 105) 100 > 95% NT
SEP-EASE (PEG) 10.9 1.1 × 106 (9.6 × 104)8 5 >  9 5 % N T
Protein A/G 8.9 1.1 × 106 (6.3 × 104)8 4 >  9 5 % N T
Protein G 14.3 1.8 × 106 (2.0 × 104) 100 > 95% NT
Malaria-Exposed Human Pre-purification 1.1 × 104 (962)
CA-AS 12.3 1.2 × 103 (176) 11* > 95% Yes
SEP-EASE (PEG) 14.5 1.6 × 104 (4 × 103) 100 > 95% Yes
Protein A/G 14.4 4.8 × 103 (95) 44* >95% No
Protein G 19.8 6.6 × 103 (2.1 × 103)6 0 >  9 5 % N o
Data expressed as mean (± SEM) of three independent purification experiments.
1Protein concentration was determined by the absorbance of the solution at 280 nm with an extinction coefficient of 13.5 (standard for IgG) for a 
1% IgG solution (10 mg/mL)
2Mean ELISA titer for an OD405 = 1, for rabbits tested against MSP1-p42(FVO) plate antigen, for humans tested against MSP1-p42(3D7) plate 
antigen
3Recovery of Ag-specific Igs is based on Mean ELISA titer.
4Determined by scanning densitometry on Coomassie Blue stained gels
5Samples were stored for 24 weeks at 4°C and then tested by SDS-gelelectrophoresis, NT = not tested
*A statistically significant difference between the methods in the recovery of Ag-specific Ab by ANOVA. The individual groups were isolated with a 
Tukey's post test (p < 0.025).
Changes in Ag-specific titers as a function of purification methods Figure 3
Changes in Ag-specific titers as a function of purification methods. Various Ig preparations from (A) rabbit sera or (B) 
human serum or plasma were tested for changes in the MSP-1p42 specific titer (i.e., OD = 1 at 405 nm). Data shown are the 
geometric mean and 95% confidence interval of three independent experiments for each purification method. Asterisks indi-
cate statistically significant differences (p < 0.05).
A
Treatment Groups
Serum CA-AS PEG Protein G Protein A/G
O
D
4
0
5
t
i
t
e
r
=
1
0.0
200.0x103
400.0x103
600.0x103
800.0x103
1.0x106
1.2x106
1.4x106
1.6x106
1.8x106
2.0x106
B
Serum CA-AS PEG Protein G Protein A/G
0
2x103
4x103
6x103
8x103
10x103
12x103
14x103
16x103
18x103
*
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Discussion
Many disease models lack correlates of immunity and
protection against infection. In models where a role for
antibodies has been established, efforts are focused
toward characterizing protective humoral immune
responses. The need to enrich or purify Ig rises from the
fact that contaminants in serum or plasma often interfere
with in vitro readout methods that are used to characterize
immune responses. Examples of contaminants that can
influence functional biological activities, either negatively
or positively are blood-borne pathogens, oxidized lipids,
chemokines, therapeutic drugs, herbal remedies as well as
other serum factors. Thus, elimination of these potential
effectors is essential in order to identify target protective
Igs.
The ability to purify Ig from sera or plasma from immune
animals or humans with a high yield and without selec-
tive loss of isotypes is imperative when conducting analyt-
ical experiments. Apart from the in vitro analysis of
humoral immune responses, Igs are frequently batch-
purified from serum for the purpose of passive transfer of
the Ig as therapeutic agents into naive animals and even
human hosts. In either case, it is imperative that the puri-
fication method does not introduce artifacts, such as a
bias in the Ig isotype, or alter the functional activity of the
antibody molecules.
Effect of purification methods on isotype subclass distribution in Ig preparations Figure 4
Effect of purification methods on isotype subclass distribution in Ig preparations. Ig preparations purified using the 
various methods were tested for changes in MSP-1p42 specific IgG1 (Panel A), IgG2 (Panel B), IgG3 (Panel C) and IgG4 (Panel 
D) for each treatment; pre-treatment serum, Protein G, Protein A/G, CA-AS, and PEG. Immune serum was from a naturally 
exposed individual residing in Gabon. Data shown are the mean OD405 (± SEM) of three independent isotype subclass specific 
ELISA experiments. Asterisks indicate statistically significant differences (p < 0.05). Dashed lines indicate background level 
responses for each isotype subclass test.
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In the present study, four frequently used Ig purification
methods were evaluated on the basis of purity of the prod-
uct, antibody specificity, isotype profile and functionality
using rabbit sera and human serum/plasma as the source
material. The results showed that the choice of the opti-
mal purification method depended upon the species from
which the sera/plasma was derived. When taking into
consideration both yield and purity, we concluded that
the highest quality Ig could be achieved using either Pro-
tein G, Protein A/G, or CA-AS and that these same meth-
ods were also the optimal Ig purification methods relative
to high-level Ag-specific Ig recovery and functionality for
rabbit IgG. For human Ig, PEG-Ig partitioning under opti-
mal conditions lead to concentrated Igs, having overall
higher recovery rates, enhanced specific activities and
yields greater than 100% presumably due to separation
from inhibitors present in the serum/plasma. This was
specifically shown by the preferential enrichment of the
IgG3 as well as the 100% recovery of IgG1, IgG2 and IgG4
subclass molecules. Both Protein G and Protein A/G puri-
fication methods yielded statistically less functional anti-
body activities compared to the source material. This may
have been caused by the, albeit transient, harsh elution
conditions which – in some cases – have been shown to
reduce antibody titer, decrease immunoreactivity and dis-
tort the antibody structure. Concomitantly, the retention
of functional antibody activities by the PEG method may
be due to the nondenaturing and reversible interactions of
the water soluble, non-ionic PEG polymers with Igs [26].
No change in Ab avidity for human and rabbit Ig by any
of the purification methods used in this study were
observed. While human Igs enriched by PEG and CA-AS
were stable when stored for extended time at 4°C, Igs
purified by Protein A/G or Protein G degraded (Figure
2C). Finally, although not specifically evaluated here,
since the role for IgM isotype in inhibitory activities
against parasites has not been defined as yet, only the
methods that preserve and retain these Ig specificities will
be useful to meeting this goal.
Conclusion
In conclusion, some considerable qualitative and quanti-
tative differences between the methods were detected that
were evaluated and, thus, Ig purification methods must be
carefully selected based on not only the animal species
from which the serum or plasma was derived, but with
regard to its intended use. For most purposes, the action
of specific antibody isotypes may not be well known thus
preservation of isotype profiles remains critical, herein, to
establishing antibody immune correlates of protection.
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Growth inhibitory activity of various Ig preparations from (A) MSP-1p42 (FVO) specific rabbit sera or (B) 
human malaria-experienced plasma was measured against FVO parasites in a pLDH based growth inhibition 
assay (GIA). Data are expressed as the mean and SEM of three independent purifications per method (sample size for all 
treatment groups n = 27 except for Protein A/G (n = 6)). Asterisk indicates statistically significant differences (p < 0.01).
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